BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 27428571)

  • 1. Vonoprazan for treatment of gastroesophageal reflux: pharmacodynamic and pharmacokinetic considerations.
    Savarino E; Martinucci I; Furnari M; Romana C; Pellegatta G; Moscatelli A; Bodini G; Marabotto E; Savarino V; de Bortoli N; Blandizzi C
    Expert Opin Drug Metab Toxicol; 2016 Nov; 12(11):1333-1341. PubMed ID: 27428571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vonoprazan fumarate for the management of acid-related diseases.
    Martinucci I; Blandizzi C; Bodini G; Marabotto E; Savarino V; Marchi S; de Bortoli N; Savarino E
    Expert Opin Pharmacother; 2017 Aug; 18(11):1145-1152. PubMed ID: 28657473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: A systematic review.
    Miyazaki H; Igarashi A; Takeuchi T; Teng L; Uda A; Deguchi H; Higuchi K; Tango T
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1316-1328. PubMed ID: 30883868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole.
    Ashida K; Iwakiri K; Hiramatsu N; Sakurai Y; Hori T; Kudou K; Nishimura A; Umegaki E
    World J Gastroenterol; 2018 Apr; 24(14):1550-1561. PubMed ID: 29662293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potassium-competitive acid blockers and acid-related disorders.
    Huang KZ; Weber HC
    Curr Opin Endocrinol Diabetes Obes; 2024 Jun; 31(3):107-114. PubMed ID: 38483115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct Comparison of the Efficacy and Safety of Vonoprazan Versus Proton-Pump Inhibitors for Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis.
    Cheng Y; Liu J; Tan X; Dai Y; Xie C; Li X; Lu Q; Kou F; Jiang H; Li J
    Dig Dis Sci; 2021 Jan; 66(1):19-28. PubMed ID: 32095968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcomes of patients with symptomatic gastroesophageal reflux disease treated with vonoprazan.
    Shinozaki S; Osawa H; Kobayashi Y; Sakamoto H; Hayashi Y; Miura Y; Kawarai Lefor A; Yamamoto H
    Scand J Gastroenterol; 2018 Aug; 53(8):897-904. PubMed ID: 30056768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438).
    Otake K; Sakurai Y; Nishida H; Fukui H; Tagawa Y; Yamasaki H; Karashima M; Otsuka K; Inatomi N
    Adv Ther; 2016 Jul; 33(7):1140-57. PubMed ID: 27287852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date.
    Sugano K
    Therap Adv Gastroenterol; 2018; 11():1756283X17745776. PubMed ID: 29383028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A study for every second day administration of vonoprazan for maintenance treatment of erosive GERD (ESD von GERD): a multicenter randomized cross-over study.
    Matsuda S; Kato M; Sakakibara Y; Hamada H; Sasaki Y; Mori H; Hirai Y; Inoue S; Toyokawa T; Kagaya T; Kuwai T; Esaka N; Yamashita H; Watanabe N; Matsumoto M; Fujii H; Demura M; Kubo K; Mabe K; Harada N
    J Gastroenterol; 2022 Mar; 57(3):133-143. PubMed ID: 35092498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale and design of the VISION study: a randomized, open-label study to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive esophagitis.
    Uemura N; Kinoshita Y; Haruma K; Yao T; Kushima R; Kanoo T
    Clin Exp Gastroenterol; 2018; 11():51-56. PubMed ID: 29416369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The potential role of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease.
    Scarpignato C; Hunt RH
    Curr Opin Gastroenterol; 2019 Jul; 35(4):344-355. PubMed ID: 31045597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, double-blind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resistant erosive esophagitis.
    Iwakiri K; Sakurai Y; Shiino M; Okamoto H; Kudou K; Nishimura A; Hiramatsu N; Umegaki E; Ashida K
    Therap Adv Gastroenterol; 2017 Jun; 10(6):439-451. PubMed ID: 28567114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacokinetics of ilaprazole for gastro-esophageal reflux treatment.
    de Bortoli N; Martinucci I; Giacchino M; Blandizzi C; Marchi S; Savarino V; Savarino E
    Expert Opin Drug Metab Toxicol; 2013 Oct; 9(10):1361-9. PubMed ID: 23802731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial.
    Laine L; DeVault K; Katz P; Mitev S; Lowe J; Hunt B; Spechler S
    Gastroenterology; 2023 Jan; 164(1):61-71. PubMed ID: 36228734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of vonoprazan in patients with erosive esophagitis.
    Zhang M; Xiao Y; Chen M
    Therap Adv Gastroenterol; 2022; 15():17562848221122623. PubMed ID: 36117573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vonoprazan 10 mg daily is effective for the treatment of patients with proton pump inhibitor-resistant gastroesophageal reflux disease.
    Shinozaki S; Osawa H; Hayashi Y; Sakamoto H; Kobayashi Y; Lefor AK; Yamamoto H
    Biomed Rep; 2017 Sep; 7(3):231-235. PubMed ID: 28894571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis.
    Ashida K; Sakurai Y; Hori T; Kudou K; Nishimura A; Hiramatsu N; Umegaki E; Iwakiri K
    Aliment Pharmacol Ther; 2016 Jan; 43(2):240-51. PubMed ID: 26559637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of the clinical development of fexuprazan for gastroesophageal reflux-related disease.
    Ramani A; Merchant A; Cash BD
    Eur J Clin Pharmacol; 2023 Aug; 79(8):1023-1029. PubMed ID: 37344679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vonoprazan versus lansoprazole in erosive esophagitis - A systematic review and meta-analysis of randomized controlled trials.
    Chandan S; Deliwala S; Mohan BP; Ramai D; Dhindsa B; Bapaye J; Kassab LL; Chandan OC; Facciorusso A; Adler DG
    Indian J Gastroenterol; 2023 Aug; 42(4):475-484. PubMed ID: 37418052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.